Jamin Koo, PhD, Stanford University, Stanford, CA, discusses a recent study which used machine learning to assist in selecting between bortezomib, melphalan, and prednisone (VMP) therapy and lenalidomide-dexamethasone (Rd) in patients with multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.